LONDON, April 9, 2014 /PRNewswire/ --
On Tuesday, April 08, 2014, the
NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones
Industrial Average advanced 0.06% to 16,256.14, and the S&P 500
closed at 1,851.96, up 0.38%. The gains were broad based as seven
out of 10 sectors ended the session in positive. The S&P 500
Health Care Sector Index finished the day at 659.34, down 0.80%,
and the same has fallen by 4.04% in the last one month.
Investor-Edge has initiated coverage on the following equities:
Endo International PLC (NASDAQ: ENDP), Dynavax Technologies Corp.
(NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX) and Orexigen
Therapeutics Inc. (NASDAQ: OREX). Free technical research on ENDP,
DVAX, FRX and OREX can be downloaded upon signing up at:
http://www.investor-edge.com/936-register
Endo International PLC's stock fell by 0.57% on Tuesday, closing at
$60.96, after oscillating between
$58.50 and $61.76. A total of 6.98
million shares were traded, which is above its three months average
volume of 2.65 million shares. Endo International PLC's shares have
declined 17.35% in the last one month and 9.64% on YTD basis. The
company's stock is trading above its 200-day moving average. Endo
International PLC's 50-day moving average of $71.12 is above its 200-day moving average of
$55.50. Furthermore, the company's
stock is trading at a PE ratio of 47.57 and has a Relative Strength
Index (RSI) of 26.61. Sign up today to read free research on ENDP
at:
http://www.investor-edge.com/936-ENDP-09Apr2014.pdf
Shares of Dynavax Technologies Corp. witnessed a trading volume of
1.65 million shares on Tuesday, as compared with its three months
average volume of 4.23 million shares. The stock ended the day at
$1.65, up 2.80%, after trading
between $1.58 and $1.67. Dynavax
Technologies Corp.'s shares have fallen by 12.70% in the last one
month and 15.82% on YTD basis. The stock is trading above its
200-day moving average. Dynavax Technologies Corp.'s 50-day moving
average of $1.81 is above its 200-day
moving average of $1.51.
Additionally, the company's shares have an RSI of 37.24. Sign up
today to read free research on DVAX at:
http://www.investor-edge.com/936-DVAX-09Apr2014.pdf
On Tuesday, shares in Forest Laboratories Inc. declined 1.52%
finishing the session at $87.22. The
stock recorded a trading volume of 7.02 million shares which is
above its three months average volume of $3.85 million shares. The stock fluctuated
between $85.30 and $88.49 during the
session. Forest Laboratories Inc.'s shares have lost 7.88% in the
last one month, while the same has rallied 25.86% in the previous
three months and 45.29% on YTD basis. The stock is trading above
its 50-day and 200-day moving averages. Forest Laboratories Inc.'s
50-day moving average of $86.50 is
above its 200-day moving average of $58.13. Moreover, the company's shares are
trading at a PE ratio of 110.66 and have RSI of 41.69. Sign up
today to read free research on FRX at:
http://www.investor-edge.com/936-FRX-09Apr2014.pdf
Orexigen Therapeutics Inc. shares recorded a trading volume of 1.52
million shares, as compared with its three months average volume of
2.49 million shares. The stock ended Tuesday's session at
$5.72, up 0.53%, and at an intraday
trading range of $5.58 and
$5.84. Shares in Orexigen
Therapeutics Inc. have gone down by 17.82% in the last one month
and 4.51% in the previous three months, while the same has gained
1.60% on YTD basis. The stock is trading below its 50-day and
200-day moving averages. Orexigen Therapeutics Inc.'s 50-day moving
average of $6.83 is above its 200-day
moving average of $6.36. Further, the
company's shares have an RSI of 29.88. Sign up today to read free
research on OREX at:
http://www.investor-edge.com/936-OREX-09Apr2014.pdf
EDITOR'S NOTES:
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge